3 research outputs found
Enhancing reuse of data and biological material in medical research : from FAIR to FAIR-Health
The known challenge of underutilization of data and biological material from biorepositories as potential resources
formedical research has been the focus of discussion for over a decade. Recently developed guidelines for improved
data availability and reusability—entitled FAIR Principles (Findability, Accessibility, Interoperability, and
Reusability)—are likely to address only parts of the problem. In this article,we argue that biologicalmaterial and data
should be viewed as a unified resource. This approach would facilitate access to complete provenance information,
which is a prerequisite for reproducibility and meaningful integration of the data. A unified view also allows for
optimization of long-term storage strategies, as demonstrated in the case of biobanks.Wepropose an extension of the
FAIR Principles to include the following additional components: (1) quality aspects related to research reproducibility
and meaningful reuse of the data, (2) incentives to stimulate effective enrichment of data sets and biological
material collections and its reuse on all levels, and (3) privacy-respecting approaches for working with the human
material and data. These FAIR-Health principles should then be applied to both the biological material and data. We
also propose the development of common guidelines for cloud architectures, due to the unprecedented growth of
volume and breadth of medical data generation, as well as the associated need to process the data efficiently.peer-reviewe
Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
Purpose Liposarcoma (LPS) represent the largest group of malignant soft tissue tumours comprising a heterogeneous group of subtypes in which the degrees of chemoresistance and radiosensitivity strongly vary. Consequently, it is of utmost interest to establish novel therapeutic regimens based on molecular targets. Methods Immunohistochemical staining of survivin was performed in tissue microarrays comprising 49 primary LPS specimens. LPS cell lines were treated with survivin antagonist YM155 and doxorubicin or etoposide alone as well as in combination. Changes in cell viability were investigated and the synergistic effect of a combined therapy analysed. Results Immunohistochemistry revealed an abundant expression of survivin in LPS that significantly concurred with less-differentiated tumour subtypes and grading. In vitro, we demonstrated the impact of the survivin inhibitor YM155 on dedifferentiated LPS (DDLPS) and, even more imposing, pleomorphic LPS (PLS) tumour cell viability with a strong induction of apoptosis. A combined treatment of doxorubicin or etoposide with YM155 augmented the cytotoxic effects on DDLPS and PLS cells. Conclusion These findings support the significant role of survivin in the oncogenesis and progression of LPS subtypes providing a rationale to target survivin in eligible in-vivo models and to pioneer clinical applications of survivin-specific substances unfolding their therapeutic potential in LPS patients prospectively
Search for High-energy Neutrinos from Binary Neutron Star Merger GW170817 with ANTARES, IceCube, and the Pierre Auger Observatory
The Advanced LIGO and Advanced Virgo observatories recently discovered
gravitational waves from a binary neutron star inspiral. A short gamma-ray
burst (GRB) that followed the merger of this binary was also recorded by the
Fermi Gamma-ray Burst Monitor (Fermi-GBM), and the Anticoincidence Shield for
the Spectrometer for the International Gamma-Ray Astrophysics Laboratory
(INTEGRAL), indicating particle acceleration by the source. The precise
location of the event was determined by optical detections of emission
following the merger. We searched for high-energy neutrinos from the merger in
the GeV--EeV energy range using the ANTARES, IceCube, and Pierre Auger
Observatories. No neutrinos directionally coincident with the source were
detected within s around the merger time. Additionally, no MeV
neutrino burst signal was detected coincident with the merger. We further
carried out an extended search in the direction of the source for high-energy
neutrinos within the 14-day period following the merger, but found no evidence
of emission. We used these results to probe dissipation mechanisms in
relativistic outflows driven by the binary neutron star merger. The
non-detection is consistent with model predictions of short GRBs observed at a
large off-axis angle.Comment: 22 pages, 2 figure